Amphastar Pharmaceuticals (AMPH) Competitors $44.61 -0.45 (-1.00%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends AMPH vs. PTGX, DYN, SNDX, FPRX, CALT, ROIV, ASND, LEGN, ELAN, and VKTXShould you be buying Amphastar Pharmaceuticals stock or one of its competitors? The main competitors of Amphastar Pharmaceuticals include Protagonist Therapeutics (PTGX), Dyne Therapeutics (DYN), Syndax Pharmaceuticals (SNDX), Five Prime Therapeutics (FPRX), Calliditas Therapeutics AB (publ) (CALT), Roivant Sciences (ROIV), Ascendis Pharma A/S (ASND), Legend Biotech (LEGN), Elanco Animal Health (ELAN), and Viking Therapeutics (VKTX). These companies are all part of the "medical" sector. Amphastar Pharmaceuticals vs. Protagonist Therapeutics Dyne Therapeutics Syndax Pharmaceuticals Five Prime Therapeutics Calliditas Therapeutics AB (publ) Roivant Sciences Ascendis Pharma A/S Legend Biotech Elanco Animal Health Viking Therapeutics Amphastar Pharmaceuticals (NASDAQ:AMPH) and Protagonist Therapeutics (NASDAQ:PTGX) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership. Do insiders & institutionals have more ownership in AMPH or PTGX? 65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are owned by institutional investors. 27.1% of Amphastar Pharmaceuticals shares are owned by company insiders. Comparatively, 5.4% of Protagonist Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has more risk and volatility, AMPH or PTGX? Amphastar Pharmaceuticals has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500. Comparatively, Protagonist Therapeutics has a beta of 2.17, indicating that its stock price is 117% more volatile than the S&P 500. Is AMPH or PTGX more profitable? Protagonist Therapeutics has a net margin of 52.76% compared to Amphastar Pharmaceuticals' net margin of 21.80%. Protagonist Therapeutics' return on equity of 34.68% beat Amphastar Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Amphastar Pharmaceuticals21.80% 26.44% 11.89% Protagonist Therapeutics 52.76%34.68%30.98% Do analysts recommend AMPH or PTGX? Amphastar Pharmaceuticals currently has a consensus price target of $63.00, suggesting a potential upside of 41.22%. Protagonist Therapeutics has a consensus price target of $53.57, suggesting a potential upside of 30.31%. Given Amphastar Pharmaceuticals' higher possible upside, equities analysts plainly believe Amphastar Pharmaceuticals is more favorable than Protagonist Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amphastar Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50Protagonist Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 Does the MarketBeat Community favor AMPH or PTGX? Amphastar Pharmaceuticals received 118 more outperform votes than Protagonist Therapeutics when rated by MarketBeat users. Likewise, 66.33% of users gave Amphastar Pharmaceuticals an outperform vote while only 60.89% of users gave Protagonist Therapeutics an outperform vote. CompanyUnderperformOutperformAmphastar PharmaceuticalsOutperform Votes39266.33% Underperform Votes19933.67% Protagonist TherapeuticsOutperform Votes27460.89% Underperform Votes17639.11% Does the media refer more to AMPH or PTGX? In the previous week, Protagonist Therapeutics had 12 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 17 mentions for Protagonist Therapeutics and 5 mentions for Amphastar Pharmaceuticals. Amphastar Pharmaceuticals' average media sentiment score of 0.63 beat Protagonist Therapeutics' score of 0.59 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amphastar Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Protagonist Therapeutics 4 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable earnings & valuation, AMPH or PTGX? Amphastar Pharmaceuticals has higher revenue and earnings than Protagonist Therapeutics. Amphastar Pharmaceuticals is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmphastar Pharmaceuticals$644.40M3.33$137.54M$3.0014.87Protagonist Therapeutics$60M40.84-$78.96M$2.6615.45 SummaryProtagonist Therapeutics beats Amphastar Pharmaceuticals on 11 of the 19 factors compared between the two stocks. Ad Genesis Gold GroupTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy with a heavy hand—building up infrastructure, slapping tariffs on imports, and going all-in on U.S. jobs. But here's the kicker: while Trump's focused on making America stronger, the Washington elite is ready to fight back…Get ahead of the game with 3 proven strategies to protect your retirement from Washington's next mov Get Amphastar Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMPH vs. The Competition Export to ExcelMetricAmphastar PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.14B$6.39B$5.06B$8.67BDividend YieldN/A8.04%5.06%4.06%P/E Ratio14.8710.1698.9217.12Price / Sales3.33266.571,205.7371.29Price / Cash10.4253.4940.6936.36Price / Book2.959.306.325.87Net Income$137.54M$154.14M$119.47M$225.66M7 Day Performance-7.66%-9.49%-5.11%-1.34%1 Month Performance-12.24%-7.23%-3.21%1.00%1 Year Performance-20.58%30.70%32.41%25.27% Amphastar Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMPHAmphastar Pharmaceuticals4.8623 of 5 stars$44.61-1.0%$63.00+41.2%-20.6%$2.14B$644.40M14.871,761Insider SellingPTGXProtagonist Therapeutics3.0657 of 5 stars$46.50+0.6%N/A+155.0%$2.74B$60M17.48125Analyst RevisionDYNDyne Therapeutics3.4735 of 5 stars$28.13-1.2%N/A+190.7%$2.82BN/A-7.84100Earnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionNews CoverageSNDXSyndax Pharmaceuticals3.4656 of 5 stars$21.78-0.1%N/A+6.9%$1.86B$139.71M-6.00110Analyst ForecastNews CoverageFPRXFive Prime TherapeuticsN/A$38.00flatN/AN/A$1.77B$14.87M-14.1887CALTCalliditas Therapeutics AB (publ)0.1943 of 5 stars$40.00flatN/AN/A$1.19B$1.60B-21.62180News CoverageROIVRoivant Sciences3.419 of 5 stars$11.81-0.5%N/A+24.2%$8.73B$158.30M2.12860Analyst ForecastNews CoverageASNDAscendis Pharma A/S3.06 of 5 stars$128.40+3.3%N/A+35.3%$7.79B$288.08M-13.79640Analyst DowngradeShort Interest ↑News CoverageGap DownLEGNLegend Biotech1.8575 of 5 stars$40.04+0.0%N/A-39.9%$7.30B$455.99M-51.331,800Earnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionNews CoverageELANElanco Animal Health3.5205 of 5 stars$14.27+1.4%N/A+21.5%$7.05B$4.42B35.669,300Short Interest ↑VKTXViking Therapeutics4.5045 of 5 stars$62.97-8.0%N/A+370.8%$7.02BN/A-67.7120 Related Companies and Tools Related Companies PTGX Competitors DYN Competitors SNDX Competitors FPRX Competitors CALT Competitors ROIV Competitors ASND Competitors LEGN Competitors ELAN Competitors VKTX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AMPH) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amphastar Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amphastar Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AMPH Stock Alerts